A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Jacqueline N PostonJonathan R FrommHeather A RasmussenAndrei R ShustovEdward N LibbyStephen D SmithTed GooleyAjay K GopalPublished in: British journal of haematology (2018)
Keyphrases